SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3.12 |
| Enterprise Value ($M) | -2.47 |
| Book Value ($M) | 8.40 |
| Book Value / Share | 12.57 |
| Price / Book | 0.37 |
| NCAV ($M) | 5.21 |
| NCAV / Share | 7.26 |
| Price / NCAV | 0.60 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.72 |
| Return on Assets (ROA) | -0.62 |
| Return on Equity (ROE) | -0.71 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.22 |
| Current Ratio | 5.07 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.28 |
| Assets | 10.47 |
| Liabilities | 2.07 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 4.60 |
| Operating Income | -8.13 |
| Net Income | -7.68 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -6.99 |
| Cash from Investing | -0.01 |
| Cash from Financing | 4.65 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | 14.86 | |
| 13G | AdvisorShares Trust | 8.77 | ||
| 13G | Sabby Management, Llc | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,229 | 25,698 | 16.46 | |
| 7,031 | 31,660 | 22.21 | |
| 27,170 | 51,274 | 52.99 | |
| 3,679 | 20,287 | 18.13 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IMTX – Immatics N.V. | INDP – Indaptus Therapeutics, Inc. |
| INKT – MiNK Therapeutics, Inc. | INMB – INmune Bio, Inc. |
| INTS – Intensity Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io